Name: Firebrick Pharma (FRE) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

FRE

Pharmaceuticals, Biotechnology & Life Sciences

Firebrick Pharma

Short interest: 0.01%; +0.01 pp 30d; as of 1 July 2026
Reported shorts: 19.2K
Shares on issue: 285.199M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Firebrick Pharma

Firebrick Pharma is a pharmaceutical development and manufacturing company focused on developing and commercializing nasal sprays based on povidone-iodine (PVP-I). Their lead product, Nasodine Nasal Spray, is intended as a treatment for the common cold. The company aims to bring Nasodine to the global market.

Company profile →

Firebrick Pharma (ASX:FRE) has 0.01% of its shares on issue reported as short positions as of 1 July 2026, or about 19,206 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. FRE is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads FRE today

Zanger BreakoutWatchScore 6rank 1910 of 1942
CAN SLIMNot a candidate
Minervini Trend TemplateWatchScore 7rank 1586 of 1716
Crowded-Short BreakoutWatchScore 9rank 1123 of 1500
Quality compoundersNot a candidate

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

FRE fundamentals

In the year to 30 Jun 2026, Firebrick Pharma (ASX:FRE) recorded revenue of A$106.0K and a net loss after tax of A$3.1M. A year earlier it recorded revenue of A$293.4K and a net loss after tax of A$2.6M. Year-on-year growth: revenue −63.9% (FY). Net margin −2,889.1% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →